Comorbidities and co-infections in people living with HIV/AIDS

It is a cross-sectional study made in three clinics specialized in the care of infectious diseases in Ribeirão Preto, SP, Brazil, in order to identify the prevalence of co-infections and comorbidities in people living with HIV / AIDS. Demographic and clinical variables were analyzed from 498 medica...

Full description

Saved in:
Bibliographic Details
Main Authors: Rosângela Casas Righetto (Author), Renata Karina Reis (Author), Lílian Andreia Fleck Reinato (Author), Elucir Gir (Author)
Format: Book
Published: Universidade Federal do Ceará, 2015-02-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_c20dd78b0dc2479d93d42aae3aad8999
042 |a dc 
100 1 0 |a Rosângela Casas Righetto  |e author 
700 1 0 |a Renata Karina Reis  |e author 
700 1 0 |a Lílian Andreia Fleck Reinato  |e author 
700 1 0 |a Elucir Gir  |e author 
245 0 0 |a Comorbidities and co-infections in people living with HIV/AIDS 
260 |b Universidade Federal do Ceará,   |c 2015-02-01T00:00:00Z. 
500 |a 10.15253/2175-6783.2014000600006 
500 |a 1517-3852 
500 |a 2175-6783 
520 |a It is a cross-sectional study made in three clinics specialized in the care of infectious diseases in Ribeirão Preto, SP, Brazil, in order to identify the prevalence of co-infections and comorbidities in people living with HIV / AIDS. Demographic and clinical variables were analyzed from 498 medical records of patients from December, 2004 to June, 2010. Data analyzed using descriptive statistics show an average of 39.3 years of age, ranging from 17 to 71 years, with 295 (59.2%) males. 390 comorbidities were observed (78.3%), especially dyslipidemia 126 (25.3%), triglycerides 68 (13.7%), hepatitis C 68 (13.7%), oral candidiasis 60 (12.0 %), sexually transmitted disease 57 (11.4%) and tuberculosis 51 (10.2%). Depending on the different comorbidities, it is considered appropriate that special strategies to monitor are planned, for the diagnosis and early intervention. 
546 |a EN 
546 |a PT 
690 |a Morbidity 
690 |a HIV 
690 |a Acquired Immunodeficiency Syndrome 
690 |a Anti-Retroviral Agents 
690 |a Nursing 
690 |a RT1-120 
655 7 |a article  |2 local 
786 0 |n Rev Rene, Vol 15, Iss 6 (2015) 
787 0 |n http://www.revistarene.ufc.br/revista/index.php/revista/article/view/1761/pdf_1 
787 0 |n https://doaj.org/toc/1517-3852 
787 0 |n https://doaj.org/toc/2175-6783 
856 4 1 |u https://doaj.org/article/c20dd78b0dc2479d93d42aae3aad8999  |z Connect to this object online.